A phase I/II trial of irinotecan-cisplatin combined with an anti-late-diarrhoeal programme to evaluate the safety and antitumour response of this combination therapy in patients with advanced non-small-cell lung cancer. [electronic resource]
Producer: 20060125Description: 1341-9 p. digitalISSN:- 0007-0920
- Administration, Oral
- Adult
- Aged
- Antacids -- administration & dosage
- Antidiarrheals -- therapeutic use
- Antineoplastic Combined Chemotherapy Protocols -- adverse effects
- Area Under Curve
- Camptothecin -- administration & dosage
- Carcinoma, Non-Small-Cell Lung -- drug therapy
- Cholagogues and Choleretics -- administration & dosage
- Cisplatin -- administration & dosage
- Diarrhea -- chemically induced
- Disease Progression
- Female
- Humans
- Infusions, Intravenous
- Irinotecan
- Lung Neoplasms -- drug therapy
- Magnesium Oxide -- administration & dosage
- Male
- Maximum Tolerated Dose
- Middle Aged
- Sodium Bicarbonate -- administration & dosage
- Survival Analysis
- Ursodeoxycholic Acid -- administration & dosage
No physical items for this record
Publication Type: Clinical Trial, Phase I; Clinical Trial, Phase II; Journal Article
There are no comments on this title.
Log in to your account to post a comment.